Wilms Tumor
Also known as: Nephroblastoma
Methodology & AI Transparency ⓘ
Wilms Tumor Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Wilms tumor is a rare type of kidney cancer.
- 2 Real-world patient consensus: Diagnostic registry C64.9: Wilms Tumor is managed within Cancer & Oncology (aka Nephroblastoma).
- 3 Typical cash cost range: Clinicians assessing Wilms Tumor focus on potential lymphatic or in Wilms Tumor (C64.9: hematogenous dissemination if) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Wilms Tumor: maintaining Comprehensive Metabolic & in Wilms Tumor (C64.9: Organ Function Panel) within Preserved renal/hepatic clearance (C64.9).
Ask our AI Specialists anything about Wilms Tumor
What Is Wilms Tumor?
Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Wilms Tumor (C64.9) features potential lymphatic or in Wilms Tumor (C64.9: hematogenous dissemination if). Cross-referenced with NIH MeSH (Wilms Tumor), therapeutic stabilization in cancer & oncology is verified against Pathology / Molecular in Wilms Tumor (C64.9: Genomic Staging).
Common Symptoms & Clinical Signs
- • Presentation of Wilms Tumor (C64.9): persistent painless lump, in Wilms Tumor (C64.9: non-healing ulcer/mole change,)
- • Secondary Wilms Tumor clinical sign: unintended weight loss [Wilms Tumor C64.9]
- • Symptom flares in Wilms Tumor correlating with Comprehensive Metabolic & in Wilms Tumor (C64.9: Organ Function Panel) deviation outside Preserved renal/hepatic clearance (C64.9)
- • Functional cancer & oncology impact requiring tissue biopsy with in Wilms Tumor (C64.9: histopathology) evaluation (C64.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Wilms Tumor Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C64.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Wilms Tumor (C64.9: Organ Function Panel) | Preserved renal/hepatic clearance (C64.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Wilms Tumor (C64.9: Genomic Staging) | Guideline-concordant surveillance (C64.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Wilms Tumor (C64.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C64.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Wilms Tumor
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Etanercept Enbrel • RxCUI RXN-58406032-2382 | Tumor Necrosis Factor Blocker | 86% | $1984.1427 | $ 185.00 /mo |
| Yusimry (Adalimumab-Aqvh) Yusimry • RxCUI 2640395 | Tumor Necrosis Factor Blocker | 81% | $604.1525 | $ 526.75 /mo |
| Certolizumab Pegol Cimzia • RxCUI 795081 | Tumor Necrosis Factor Blocker | 77% | $5783.3464 | $ 185.00 /mo |
| Renflexis (Infliximab) Renflexis • RxCUI 1927290 | Tumor Necrosis Factor Blocker | 80% | $0.2500 | $ 26.50 /mo |
| Adalimumab-Adaz Hyrimoz • RxCUI RXN-83457102-2276 | Tumor Necrosis Factor Blocker | 83% | $1586.7323 | $ 185.00 /mo |
| Simlandi (Adalimumab-Ryvk) Simlandi • RxCUI 2677780 | FDA Prescription Therapeutic Agent | 84% | $478.6490 | $ 640.00 /mo |
| Amjevita (Adalimumab-Atto) Amjevita • RxCUI 2627711 | Tumor Necrosis Factor Blocker | 92% | $872.7719 | $ 640.00 /mo |
| Infliximab-Axxq Avsola • RxCUI RXN-55513670-3213 | Tumor Necrosis Factor Blocker | 75% | $1.2300 | $ 58.32 /mo |
| Simponi Aria (Golimumab) Simponi Aria • RxCUI 1431647 | Tumor Necrosis Factor Blocker | 90% | $2.4900 | $ 187.78 /mo |
| Cimzia (Certolizumab Pegol) Cimzia • RxCUI 795085 | Tumor Necrosis Factor Blocker | 93% | $5783.3464 | $ 640.00 /mo |
| Hadlima (Adalimumab-Bwwd) Hadlima • RxCUI RXN-B500906707 | Tumor Necrosis Factor Blocker | 82% | $1254.6130 | $ 640.00 /mo |
| Infliximab-Dyyb Zymfentra, Inflectra • RxCUI RXN-72606025-2721 | Tumor Necrosis Factor Blocker | 90% | $3.1100 | $ 134.45 /mo |
| Golimumab Simponi Aria, Simponi • RxCUI 1431642 | Tumor Necrosis Factor Blocker | 89% | $12356.6836 | $ 185.00 /mo |
| Zymfentra (Infliximab-Dyyb) Zymfentra • RxCUI RXN-B72606025 | Tumor Necrosis Factor Blocker | 82% | $2.9600 | $ 221.62 /mo |
| Adalimumab-Aqvh Yusimry • RxCUI 2640389 | Tumor Necrosis Factor Blocker | 88% | $604.1525 | $ 185.00 /mo |
| Infliximab Renflexis, Remicade • RxCUI 1927285 | Tumor Necrosis Factor Blocker | 74% | $1135.9660 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Wilms Tumor)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Treatment with ramucirumab plus paclitaxel maintained QoL and performance status over time compared with placebo plus paclitaxel in the Japan subgroup of the RAINBOW trial. Clinical drug investigation • 2021-01-15 • Phase III Randomized Trial | N = 68 | 88/100 | PMID 33355909 ↗ |
| New Insights on Molecular profile-based recommendations for postoperative add-on treatment in: What a 590-Participant Study Found Secondary outcomes are relapse-free survival, overall survival, side effects and health-related cancer-specific quality of life. Journal of gynecologic oncology • 2023-03-15 • Phase III Randomized Trial | N = 590 | 87/100 | PMID 36659832 ↗ |
| Can This Approach Help? Inside the Latest Research on Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT This study demonstrates that AV without anthracyclines is sufficient to achieve NSS and good survival in the majority of patients. British journal of cancer • 2024-10-15 • Phase III Randomized Trial | N = 174 | 82/100 | PMID 39080350 ↗ |
| Can This Approach Help? Inside the Latest Research on Interim analysis in clinical trials: caution against premature conclusions-the S0777's success underscores the importance of pre-specified interim monitoring plans and cautions against premature trial termination. Trials • 2026-08-27 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42661196 ↗ |
| Can This Approach Help? Inside the Latest Research on Ulinastatin in the treatment of radiotherapy-induced oral mucositis in The 3-year overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) in UTI group and control group are similar between two groups. Nature communications • 2025-03-23 • Phase III Randomized Trial | N = 89 | 82/100 | PMID 40122906 ↗ |
Wilms Tumor Patient Community & “People Like Me” Threads
Filter Wilms Tumor community threads and patient logs by age, biological sex, dosage, and treatment duration.